Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out drugs are emerging.

Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...

The Rock River Valley Blood Center will reward donors with free marijuana to inspire donations on Saturday. The “Bleed for Weed” blood drive will take place at the RRVBC’s Belvidere location, 1740 S ...

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...

Medtech shouldn’t be greatly impacted if vaccine critic Robert F. Kennedy Jr. is appointed as secretary of the U.S.

Wolfe projects a positive outlook for Pharma & Large-Cap Biotech stocks despite potential policy changes as part of Make America Healthy Again movement. Read more here.

Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

Lilly filed a lawsuit Nov. 14 against HHS head Xavier Becerra and the Health Resources and Services Administration for blocking a plan to change its 340B program from immediate discounts to offering ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

Eli Lilly sued the Health Resources and Services Administration (HRSA) for allegedly blocking the pharma giant's proposal to ...

Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...